Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing...

Area of Science:

• Dermatology and Immunology
• Inflammatory Skin Diseases

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition with limited systemic treatment options.
• Systemic steroids, previously the only FDA-approved option, have drawbacks including rebound and are not guideline-recommended.
• Off-label immunosuppressants carry risks, leaving many moderate-to-severe AD patients undertreated.

Purpose of the Study:

• To provide expert recommendations for integrating novel systemic therapies into AD management.
• To guide clinicians on assessing AD severity, treatment response, and failure in the context of new treatments.
• To address the gap between guideline updates and the timely incorporation of innovative therapies.

Main Methods:

• Literature review on AD immunopathogenesis and novel therapies.
• Expert opinion from a steering committee of dermatologists and allergists.
• Development of practical recommendations for clinical use.

Main Results:

• Dupilumab, a targeted systemic therapy, was FDA-approved in 2017 for moderate-to-severe AD.
• New therapies necessitate updated clinical guidance beyond existing national guidelines.
• Expert recommendations offer practical strategies for managing AD with novel treatments.

Conclusions:

• Expert consensus provides timely guidance for incorporating new systemic therapies in AD management.
• These recommendations aid clinicians in assessing disease severity and treatment outcomes.
• The evolving landscape of AD treatment requires adaptive clinical strategies.